Merger & Acquisition
-
【Acquisition of Manufacturing Facilities】Seeking pharmaceutical/healthcare CMO/CDMO manufacturing facilities in the United States, Europe, United Kingdom, and Australia. Budget: USD 10 million
If your company is interested in this opportunity, please contact DrugTimes BD team as soon as possible!
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
-
The biggest biotech financing of the year has been born! Who will be the next “buyer”?
What will be the fate of this new player in autoimmune diseases in the future?
-
Who will acquire Legend Bio for 13B to 15B USD? Could it be J&J?
Will J&J be the buyer? Please share your thoughts!~
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
-
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Congratulations to Lilly and Morphic! This acquisition will expand Lilly’s immunology pipeline with oral integrin therapies
-
How Do American and European Biotech Companies Make Money Using Chinese New Drugs? Sharing Successful Cases of LIDLO, LIDMA, and LIDIPO
Welcome friends to share your views in the comments section! DrugTimes will continue to pay close attention and follow up on the reports
